One‐year follow‐up of neurobehavioral therapy in functional seizures or epilepsy with traumatic brain injury: A nonrandomized controlled trial
Ryan Van Patten,Andrew Blum,Stephen Correia,Noah S. Philip,Jane B. Allendorfer,Tyler E. Gaston,Adam Goodman,Leslie P. Grayson,Krista Tocco,Valerie Vogel,Amber Martin,Samantha Fry,Mark Bolding,Lawrence Ver Hoef,Grayson L. Baird,Jerzy P. Szaflarski,W. Curt LaFrance
DOI: https://doi.org/10.1111/epi.18137
IF: 6.74
2024-10-12
Epilepsia
Abstract:Objective Patients with traumatic brain injury (TBI) often present with seizures (functional and/or epileptic), but treatments for patients with TBI and seizures are limited. We examined treatment phase and 1‐year post‐enrollment outcomes following neurobehavioral therapy (NBT) for patients with TBI + functional seizures (FS) and TBI + epilepsy. Methods In this multicenter, prospective, three‐group, nonrandomized, controlled trial, with 1‐year post‐enrollment follow‐up, three cohorts of adults were recruited: TBI + video‐electroencephalography (EEG)‐confirmed FS (n = 89), TBI + EEG‐confirmed epilepsy (n = 29), and chart/history‐confirmed TBI without seizures (n = 75). Exclusion criteria were recent psychotic or self‐injurious behavior, current suicidal ideation, pending litigation or long‐term disability, active substance use disorder, and inability to participate in study procedures. TBI + FS and TBI + epilepsy groups completed NBT for seizures, an evidence‐based, 12‐session, multimodal psychotherapy, whereas TBI without seizures participants received standard medical care. The primary outcome was change in seizure frequency; secondary outcomes were changes in mental health, TBI‐related symptoms, disability, and quality of life. Results Reductions in average monthly seizures occurred during treatment in TBI + FS participants (p = .002) and were significant from baseline (mean = 16.75; 95% confidence interval [CI] = 11.44–24.53) to 12 months post‐enrollment (mean = 7.28, 95% CI = 4.37–12.13, p = .002, d = .38). Monthly seizures decreased during treatment in TBI + epilepsy participants (p = .002); reductions were not statistically significant from baseline (mean = 2.38, 95% CI = 1.12–5.04) to 12‐month postenrollment (mean = .98, 95% CI = .40–2.42, p = .07, d = .22). Regarding treatment‐phase changes in secondary outcome measures, TBI + FS participants improved significantly on 10 of 19 variables (52.6%), TBI + epilepsy participants improved on five of 19 (26.3%), and TBI‐only comparisons improved on only one of 19 (5.3%). Significance NBT benefited patients with TBI + FS and TBI + epilepsy. Improvements were demonstrated at 1 year post‐enrollment in those with TBI + FS. NBT may be a clinically useful treatment for patients with seizures.
clinical neurology